MX387331B - Composiciones y metodos para induccion de celulas th17. - Google Patents

Composiciones y metodos para induccion de celulas th17.

Info

Publication number
MX387331B
MX387331B MX2016013247A MX2016013247A MX387331B MX 387331 B MX387331 B MX 387331B MX 2016013247 A MX2016013247 A MX 2016013247A MX 2016013247 A MX2016013247 A MX 2016013247A MX 387331 B MX387331 B MX 387331B
Authority
MX
Mexico
Prior art keywords
cells
induction
compositions
methods
bacteria
Prior art date
Application number
MX2016013247A
Other languages
English (en)
Other versions
MX2016013247A (es
Inventor
Hidetoshi Morita
Kenya Honda
Koji Atarashi
Masahira Hattori
Original Assignee
Riken
School Corporation Azabu Veterinary Medicine Educational Inst
Univ Tokyo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Riken, School Corporation Azabu Veterinary Medicine Educational Inst, Univ Tokyo filed Critical Riken
Publication of MX2016013247A publication Critical patent/MX2016013247A/es
Publication of MX387331B publication Critical patent/MX387331B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A61K2035/115—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A61K2039/55594—Adjuvants of undefined constitution from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere a cepas de bacterias derivadas de humanos a partir de muestras fecales complejas y se ha mostrado que inducen acumulación de células Th17 en el intestino y promueven funciones inmunes. Las composiciones farmacéuticas que contienen estas bacterias pueden ser usadas como anti-infecciosas y como auxiliares en vacunas mucosas.
MX2016013247A 2014-04-10 2015-04-10 Composiciones y metodos para induccion de celulas th17. MX387331B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461978182P 2014-04-10 2014-04-10
PCT/JP2015/061771 WO2015156419A1 (en) 2014-04-10 2015-04-10 Compositions and methods for induction of th17 cells

Publications (2)

Publication Number Publication Date
MX2016013247A MX2016013247A (es) 2017-05-03
MX387331B true MX387331B (es) 2025-03-18

Family

ID=54287989

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016013247A MX387331B (es) 2014-04-10 2015-04-10 Composiciones y metodos para induccion de celulas th17.

Country Status (9)

Country Link
US (3) US10300137B2 (es)
EP (1) EP3129035B1 (es)
JP (2) JP6617935B2 (es)
KR (1) KR102377396B1 (es)
CN (1) CN106659746A (es)
AU (2) AU2015244700B2 (es)
CA (1) CA2944846C (es)
MX (1) MX387331B (es)
WO (1) WO2015156419A1 (es)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ899700A0 (en) 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
WO2011151941A1 (ja) 2010-06-04 2011-12-08 国立大学法人東京大学 制御性ｔ細胞の増殖または集積を誘導する作用を有する組成物
GB201112091D0 (en) 2011-07-14 2011-08-31 Gt Biolog Ltd Bacterial strains isolated from pigs
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
DK3569690T3 (da) 2011-12-01 2024-11-11 Univ Tokyo Human-afledte bakterier som inducerer proliferation eller akkumulation af regulatoriske t-celler
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
MX387331B (es) 2014-04-10 2025-03-18 Riken Composiciones y metodos para induccion de celulas th17.
SI3065748T1 (en) 2014-12-23 2018-05-31 4D Pharma Research Limited Severe bacteroid tethethioomycron and its use in reducing inflammation
SI3193901T1 (en) 2014-12-23 2018-06-29 4D Pharma Research Limited Pirin polypeptide and immune modulation
MA41010B1 (fr) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
SI3360559T1 (sl) 2015-06-15 2020-02-28 4D Pharma Research Limited Sestavki, ki vsebujejo bakterijske seve
SG10201912326QA (en) 2015-06-15 2020-02-27 4D Pharma Res Ltd Compositions comprising bacterial strains
MA41060B1 (fr) 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
HRP20191949T1 (hr) 2015-06-15 2020-01-24 4D Pharma Research Limited Blautia stercosis i wexlerae za upotrebu u liječenju upalnih i autoimunih bolesti
EP3209310B1 (en) 2015-11-20 2018-01-31 4D Pharma Research Limited Compositions comprising bacterial strains
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520638D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520631D0 (en) * 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
EP3313423B1 (en) 2016-03-04 2019-04-24 4D Pharma Plc Compositions comprising bacterial blautia strains for treating visceral hypersensitivity
GB201612191D0 (en) 2016-07-13 2016-08-24 4D Pharma Plc Compositions comprising bacterial strains
WO2017160944A2 (en) * 2016-03-15 2017-09-21 The Regents Of The University Of Michigan Compositions and methods for treating and preventing graft versus host disease
CA3021247A1 (en) * 2016-04-19 2017-10-26 Genome Research Limited A therapeutic composition comprising at least one isolated bacterium from human stool samples and use thereof for treating dysbiosis
KR102658297B1 (ko) 2016-06-14 2024-04-18 베단타 바이오사이언시즈, 인크. 클로스트리디움 디피실레 감염의 치료
US9999641B2 (en) 2016-06-14 2018-06-19 Vedanta Biosciences, Inc. Treatment of clostridium difficile infection
TW201821093A (zh) 2016-07-13 2018-06-16 英商４Ｄ製藥有限公司 包含細菌菌株之組合物
BR112019006041A2 (pt) 2016-09-27 2019-09-03 Board Of Regents, The University Of Texas System métodos para aprimorar a terapia de bloqueio do ponto de verificação imunológico por modulação do microbioma
GB201621123D0 (en) 2016-12-12 2017-01-25 4D Pharma Plc Compositions comprising bacterial strains
CA3045098C (en) 2016-12-23 2021-08-10 Keio University Compositions and methods for the induction of cd8+ t-cells
AU2018218256A1 (en) * 2017-02-07 2019-09-26 California Institute Of Technology Modulation of gut microbiota in Huntington's disease and Rett syndrome
CA3058943C (en) 2017-04-03 2023-10-17 Gusto Global, Llc Rational design of microbial-based biotherapeutics
SI3630136T1 (sl) 2017-05-22 2021-08-31 4D Pharma Research Limited Sestave, ki zajemajo bakterijske seve
EP3630942B1 (en) 2017-05-24 2022-11-30 4D Pharma Research Limited Compositions comprising bacterial strain
MD3600363T2 (ro) 2017-06-14 2021-05-31 4D Pharma Res Ltd Compoziții cuprinzând tulpini bacteriene
WO2018229236A2 (en) 2017-06-14 2018-12-20 4D Pharma Research Limited Compositions comprising bacterial strains
SMT202000695T1 (it) 2017-06-14 2021-01-05 4D Pharma Res Limited Composizioni comprendenti ceppi batterici
WO2019051789A1 (zh) * 2017-09-15 2019-03-21 深圳华大生命科学研究院 粪厌氧棒形菌(Anaerofustis stercorihominis)及其应用
US10507221B2 (en) 2017-11-09 2019-12-17 Vedanta Biosciences, Inc. Compositions and methods for the treatment of allergy
EP3706767A4 (en) * 2017-11-09 2021-12-15 Vedanta Biosciences, Inc. COMPOSITIONS AND METHODS FOR THE TREATMENT OF AN ALLERGY
US12053495B2 (en) 2017-12-11 2024-08-06 Vedanta Biosciences, Inc. Compositions and methods for suppressing pathogenic organisms
AU2019217041B2 (en) * 2018-02-09 2022-09-15 Keio University Compositions and methods for the induction of CD8+ T-cells
WO2019169168A1 (en) * 2018-02-28 2019-09-06 Evelo Biosciences, Inc. Compositions and methods for treating cancer using agathobaculum
US12161680B2 (en) 2018-08-17 2024-12-10 Vedanta Biosciences, Inc. Methods of decreasing dysbiosis and restoring a microbiome
TW202023590A (zh) * 2018-08-17 2020-07-01 英商4D製藥研究有限公司 包含細菌菌株之組合物
JP7444459B2 (ja) * 2018-10-04 2024-03-06 国立研究開発法人理化学研究所 ＩＬＣ２を標的としたＩｇＡ産生誘導方法
WO2020146610A1 (en) * 2019-01-11 2020-07-16 President And Fellows Of Harvard College Harnessing inflammation to treat neurodevelopmental disorders
WO2021081676A1 (en) * 2019-11-01 2021-05-06 Uti Limited Partnership Harnessing the power of microbiota and metabolites for the treatment of cancer
GB202007452D0 (en) 2020-05-19 2020-07-01 Microbiotica Ltd Threrapeutic bacterial composition
CN112899194B (zh) * 2021-02-08 2022-07-12 澳优乳业（中国）有限公司 一株短双歧杆菌及其培养方法和用途
US20240316119A1 (en) 2021-02-18 2024-09-26 Vedanta Biosciences, Inc. Compositions and methods for suppressing pathogenic organisms
WO2024044787A2 (en) * 2022-08-26 2024-02-29 The Trustees Of Columbia University In The City Of New York Treatment of metabolic syndrome and associated morbidities using intestinal th17 cells or intestinal th17 cell-derived molecules
JP7279983B1 (ja) 2022-09-21 2023-05-23 学校法人近畿大学 腸内細菌培養組培地、及び腸内細菌培養方法。

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59128333A (ja) * 1983-01-07 1984-07-24 Nisshin Flour Milling Co Ltd 家禽用発育促進剤
JP3269890B2 (ja) * 1993-08-25 2002-04-02 株式会社ヤクルト本社 ワクチンの効果増強剤及び効果増強食品
US6368586B1 (en) 1996-01-26 2002-04-09 Brown University Research Foundation Methods and compositions for enhancing the bioadhesive properties of polymers
US5951977A (en) 1997-10-14 1999-09-14 The United States Of America, As Represented By The Secretary Of Agriculture Competitive exclusion culture for swine
US6319958B1 (en) 1998-06-22 2001-11-20 Wisconsin Alumni Research Foundation Method of sensitizing microbial cells to antimicrobial compound
KR100671879B1 (ko) * 1999-07-16 2007-01-19 가부시키가이샤 쇼에이 니트로이미다졸 함유 피부 질환용 외용제
AUPQ899700A0 (en) * 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
JP4553589B2 (ja) * 2002-02-21 2010-09-29 メディミューン，エルエルシー 組換えパラインフルエンザウイルス発現系とメタニューモウイルスから得られる異種抗原を含むワクチン
HRP20050258A2 (en) * 2002-08-26 2005-10-31 S.L.A. Pharma Ag A pharmaceutical composition
WO2006097949A1 (en) * 2005-03-16 2006-09-21 Actial Farmacêutica, Lda. Mixture of at least 6 species of lactic acid bacteria and/or bifidobacteria in the manufacture of sourdough
ES2563242T3 (es) * 2007-03-19 2016-03-11 Morishita Jintan Co., Ltd. Vacuna oral
JP2010155801A (ja) * 2008-12-26 2010-07-15 Ajinomoto Co Inc Ｉｌ−１７産生阻害剤及び炎症性腸疾患の治療若しくは予防剤
JP2011032170A (ja) * 2009-07-29 2011-02-17 Morinaga Milk Ind Co Ltd ヒト細胞ｉｌ−１７産生抑制剤
KR101613600B1 (ko) * 2009-12-21 2016-04-20 삼성전자주식회사 화상형성장치 및 ｘｐｓ 파일 식별방법
EP2515661A4 (en) * 2009-12-23 2013-11-13 Vaxgene Corp IMMUNE PROTECTION THROUGH ORAL ADMINISTRATION OF MINI-CAPSULES WITH RECOMBINANT LACTOCOCCUS LACTIS
FI20105478A0 (fi) * 2010-04-30 2010-04-30 Valtion Teknillinen Menetelmä tyypin 1 diabeteksen diagnosoimiseksi ja menetelmiä ja koostumuksia tyypin 1 diabeteksen puhkeamisen estämiseksi
WO2011151941A1 (ja) 2010-06-04 2011-12-08 国立大学法人東京大学 制御性ｔ細胞の増殖または集積を誘導する作用を有する組成物
DK3569690T3 (da) * 2011-12-01 2024-11-11 Univ Tokyo Human-afledte bakterier som inducerer proliferation eller akkumulation af regulatoriske t-celler
US20140357499A1 (en) * 2013-05-30 2014-12-04 Washington University METHODS OF LOW ERROR AMPLICON SEQUENCING (LEA-Seq) AND THE USE THEREOF
MX387331B (es) 2014-04-10 2025-03-18 Riken Composiciones y metodos para induccion de celulas th17.

Also Published As

Publication number Publication date
WO2015156419A1 (en) 2015-10-15
US20190290753A1 (en) 2019-09-26
AU2015244700A1 (en) 2016-11-24
JP2020014483A (ja) 2020-01-30
MX2016013247A (es) 2017-05-03
EP3129035A1 (en) 2017-02-15
AU2020273293A1 (en) 2020-12-17
US20220072125A1 (en) 2022-03-10
CN106659746A (zh) 2017-05-10
JP2017515890A (ja) 2017-06-15
US20170028061A1 (en) 2017-02-02
EP3129035B1 (en) 2024-09-18
CA2944846A1 (en) 2015-10-15
EP3129035A4 (en) 2018-03-28
CA2944846C (en) 2023-01-03
EP3129035C0 (en) 2024-09-18
JP6617935B2 (ja) 2019-12-11
US10300137B2 (en) 2019-05-28
KR20170015286A (ko) 2017-02-08
AU2015244700B2 (en) 2020-08-27
US11826424B2 (en) 2023-11-28
KR102377396B1 (ko) 2022-03-22

Similar Documents

Publication Publication Date Title
MX387331B (es) Composiciones y metodos para induccion de celulas th17.
IL282352B (en) Methods for producing autologous t cells useful to treat b cell malignancies and other cancers and compositions thereof
EA201692498A1 (ru) Способы сбора культур клеток млекопитающих
IL251951A0 (en) Methods and compositions for natural killer cells
IL255631B (en) Compositions and methods for screening t cells with antigens for specific populations
HUE036362T2 (hu) Baktériumtörzseket tartalmazó készítmények
HUE058252T2 (hu) Baktériumtörzseket tartalmazó készítmények
IL252114A0 (en) A bioreactor using macroalgae
HUE046681T2 (hu) Baktériumtörzseket tartalmazó készítmények
IL246645B (en) Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells
MX2020000621A (es) Composiciones para usarse en inmunomodulacion.
AU357468S (en) Vacuum cleaner
MA41433A (fr) Cellules immunitaires universelles pour l'immunothérapie anticancéreuse
SG11201702857PA (en) Recombinant listeria vaccine strains and methods of using the same in cancer immunotherapy
GB2541150B (en) Improvements in and relating to sample collection
ZA202000574B (en) Mesenchymal stem cells as vaccine adjuvants and methods for using the same
EP3216201A4 (en) System and method for sorting scanned documents to selected output trays
ZA201608607B (en) Novel fluoroquinolones and use thereof to treat bacterial infections
HK1237813A1 (en) Recombinant listeria vaccine strains and methods of using the same in cancer immunotherapy
TH1501007310A (th) ภาชนะเพาะเลี้ยงและวิธีเพาะเลี้ยง
HUP1500443A2 (en) Improved tissue culture method for the elimination of viruses in grapevine
TH1601002531A (th) กรดนิวคลีอิกและวิธีการสำหรับการตรวจหาเชื้อก่อโรคและจุลินทรีย์ที่เป็นประโยชน์
TH1501005877A (th) องค์ประกอบและวิธีสำหรับการเพิ่มเสถียรภาพของจุลินทรีย์
TH1501006330A (th) แบคทีเรียที่อยู่ในจีนัสแลคโตบาซิลลัส
GB2550625A (en) Identification of biological samples